文献速递系统性红斑狼疮

羟氯喹使用与系统性红斑狼疮患者新发房颤风险降低相关

Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2021-01-01

该回顾性队列研究纳入2014年12月至2017年5月的1647例成人SLE患者,其中917例使用羟氯喹、730例未使用。共发生23例新发房颤(用药组3例、未用药组20例),校正混杂因素后羟氯喹使用与新发房颤风险降低相关(OR 0.12,95%CI 0.034-0.39,P=0.0005),室性心律失常未见显著关联。

要点

  • 羟氯喹使用与新发房颤风险降低相关(OR 0.12,95%CI 0.034-0.39)。
  • 室性心律失常复合终点未见显著关联(OR 2.39,95%CI 0.25-23.0,P=0.45)。
  • 结果在完全校正模型和倾向评分匹配模型中仍显著。

核心结论

  • 在这项探索性研究中,羟氯喹使用与SLE患者新发房颤风险降低88%相关。
  • 考虑到SLE患者心血管风险升高,将羟氯喹纳入治疗方案可能对疾病表现和降低房颤风险均有益。

研究设计与样本

  • 研究为回顾性队列,纳入2014年12月1日至2017年5月30日的成人SLE患者。
  • 共纳入1647例SLE患者,其中羟氯喹使用者917例、非使用者730例。
  • 主要结局为新发房颤,次要结局为室性心律失常复合终点(室速、室颤或尖端扭转型室速)。
  • 结局通过电子健康记录审查裁定,统计分析包括简单和多因素logistic回归及倾向评分匹配分析。

主要发现

  • 共发生23例房颤事件,其中羟氯喹使用者3例、非使用者20例。
  • logistic回归分析显示羟氯喹使用与新发房颤的OR为0.12(95%CI 0.034-0.39,P=0.0005)。
  • 室性心律失常的OR为2.39(95%CI 0.25-23.0,P=0.45)。
  • 结果在完全校正模型和倾向评分匹配模型中仍显著。

临床怎么用

  • 对于SLE患者,可考虑将羟氯喹纳入治疗方案,以兼顾疾病表现控制和降低新发房颤风险。
  • 该获益需在进一步研究中确认,尤其应关注羟氯喹抗房颤作用的验证。

局限性

  • 本研究为探索性研究,需要进一步研究确认这种相对安全且低成本药物的抗房颤获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the relationship between hydroxychloroquine (HCQ) use and new-onset atrial fibrillation in patients with systemic lupus erythematosus (SLE). METHODS: A retrospective cohort of adult patients with SLE was constructed from December 1, 2014 to May 30, 2017. Patients were categorized as either HCQ users or nonusers. The primary outcome was incident atrial fibrillation. Secondary outcomes included incident ventricular arrhythmias (composite of ventricular tachycardia, ventricular fibrillation, or torsades de pointes). Outcomes were adjudicated by review of the electronic health record. Statistical analyses included simple and multivariable logistic regression tests to estimate the association between HCQ use and incident atrial fibrillation after adjusting for relevant confounders. Propensity score matching analysis was completed. RESULTS: Our study included 1,647 patients with SLE, of which 917 were HCQ users and 730 were nonusers. A total of 23 atrial fibrillation events occurred, including 3 in HCQ users and 20 in nonusers. Logistic regression analysis showed an odds ratio (OR) of 0.12 (95% confidence interval [95% CI] 0.034-0.39, P = 0.0005) for incident atrial fibrillation and 2.39 (95% CI 0.25-23.0, P = 0.45) for ventricular arrhythmias. Results remained significant in the fully adjusted and propensity score-matched models. CONCLUSION: In this exploratory study, HCQ use was associated with an 88% decrease in the risk of incident atrial fibrillation in patients with SLE. Considering the increased cardiovascular risk in SLE, incorporation of HCQ into the regimen may be beneficial for both disease manifestations and reducing the risk of atrial fibrillation. Further studies would be needed to confirm the antifibrillatory benefit of this relatively safe and low-cost medication.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Gupta A, Shields KJ, Manzi S, et al. Association of Hydroxychloroquine Use With Decreased Incident Atrial Fibrillation in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2021. PMID: 33098269. doi:10.1002/acr.24494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。